Exit

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.

Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.

UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.

The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

Stanford-StartX Fund is set to exit payment processing technology provider Poynt in an acquisition sized at up to $365m.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.